Get started
Author

Stijn Vanden Branden

Observed names: S Vanden Branden, S. Vanden Branden
OpenAlex ID: A5028681545
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
2022 · Laurent Peyrin-Biroulet, Jean-François Rahier, et al. · Clinical Gastroenterology and Hepatology · 42
PDF
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort
2018 · Peter Bossuyt, Filip Baert, et al. · Inflammatory Bowel Diseases · 33
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study
2018 · Saartje Van de Vondel, Filip Baert, et al. · Inflammatory Bowel Diseases · 25
PDF
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study
2022 · Aurelien Amiot, Jean-Francois Rahier, et al. · Journal of Crohn s and Colitis · 18
PDF
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study
2023 · Pauline Lemmens, Edouard Louis, et al. · Clinical Gastroenterology and Hepatology · 15
PDF
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
2020 · A Cremer, T Lobaton, et al. · Journal of Crohn s and Colitis · 10
PDF
Capsule endoscopy findings in cirrhosis with portal hypertension: A prospective study
2008 · D. Urbain, S. Vandebosch, et al. · Digestive and Liver Disease · 10
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapy
2025 · Edouard Louis, Peter Bossuyt, et al. · Digestive and Liver Disease · 4
PDF
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN)
2025 · Tom Holvoet, Marie Truyens, et al. · Journal of Clinical Medicine · 3
PDF
P396 Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
2021 · T De Somer, N Deprez, et al. · Journal of Crohn s and Colitis · 3
P281 Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel Disease
2021 · N Deprez, T De Somer, et al. · Journal of Crohn s and Colitis · 1
PDF
Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY
2020 · Anneline Cremer, Triana Lobaton, et al. · Gastroenterology · 1
P600 Vedolizumab dose optimisation: Findings from a Belgian registry
2020 · E Louis, V Muls, et al. · Journal of Crohn s and Colitis · 1
PDF
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
2020 · E Louis, V Muls, et al. · Journal of Crohn s and Colitis · 1
PDF
P438 Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
2017 · S. Van de Vondel, F. Baert, et al. · Journal of Crohn s and Colitis · 1
Mo1528 WILLINGNESS TO SWITCH FROM OPTIMIZED INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN IBD PATIENTS: BASELINE CHARACTERISTICS FROM THE AMARETTO TRIAL.
2026 · Annick Moens, Tom Holvoet, et al. · Gastroenterology
Mo1528 WILLINGNESS TO SWITCH FROM OPTIMIZED INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN IBD PATIENTS: BASELINE CHARACTERISTICS FROM THE AMARETTO TRIAL.
2026 · Annick Moens, Tom Holvoet, et al. · Gastrointestinal Endoscopy
P1157 Willingness to switch from optimized intravenous to subcutaneous infliximab in IBD: baseline characteristics from the AMARETTO trial
2026 · A Moens, T Holvoet, et al. · Journal of Crohn s and Colitis
Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure
2025 · A Cremer, A Mansour, et al. · Acta gastro-enterologica belgica
PDF
P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn’s disease from a Belgian registry
2021 · E Louis, V Muls, et al. · Journal of Crohn s and Colitis
P131 Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry
2019 · E Louis, V Muls, et al. · Journal of Crohn s and Colitis
Works count: 21
Citation count: 168
H-index: 7
I10-index: 7
Year
Topic
Type